Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia

main
Website

Published by Badan Analisis dan Pengembangan Ilmiah Nasional ISMKI

ISSN : 23026391 EISSN : 27211924 DOI : https://doi.org/10.53366/jimki

Core Subject : Health,

Health Professions Medicine & Pharmacology Public Health

Jurnal Ilmiah Mahasiswa Kedokteran Indonesia (JIMKI) adalah jurnal yang dikelola oleh Badan Analisis dan Pengembangan Ilmiah Nasional (BAPIN). JIMKI berfokus menjadi wadah untuk publikasi penelitian mahasiswa kedokteran.

Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)

Articles 20 Documents

1 2

Search results for , issue "Book of Abstrack RCIMS 2025" : 20 Documents clear

AI-Powered De Novo Antibiotics Discovery: Is It The Answer to Overcome Antimicrobial Resistance? A Systematic Review of Preclinical Evidence Across In Vitro and In Vivo Studies Nabilah Nurul Iftitah; Nurfajrianty Jamaluddin; Alia Zhafira Agus
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.933

Introduction. Antimicrobial resistance (AMR) remains a critical global issue. By 2050, it is projected to cause around 10 million deaths if current trends persist. Traditional antimicrobial discovery struggles to keep up with rapidly evolving resistance due to its lengthy process, high cost, and high failure rate. Developing a single drug can take over a decade of research and cost millions of dollars. These challenges demand more efficient approaches, with artificial intelligence (AI) offering a promising path to accelerate and improve antibiotic development. Methods. GoogleScholar, PubMed, ScienceDirect, and Scopus were systematically searched following the PRISMA 2020, yielding 13 eligible studies. All included in vitro validation, and four extended to in vivo investigations. Risk of bias was evaluated using the QUIN (in vitro) and the SYRCLE (in vivo) tools. Result and Discussions. Across studies, AI supported multiple stages of antibiotic discovery, including target identification, lead compound optimization, also enhancement of pre-clinical testing. In target identification, two studies revealed novel antibacterial targets distinct from classical pathway. During lead optimization, applied in most studies, AI-generated compounds demonstrated strong antimicrobial activity and low MIC values against broad-spectrum and multi-drug resistant bacteria. Four in vivo studies further showed that these de novo antibiotics exhibited superior antimicrobial efficacy to current standard therapies. Finally, in preclinical testing, AI models accurately predicted cytotoxicity and hemolysis, later confirmed experimentally. Conclusions. AI has markedly improved efficiency and accuracy in antibiotic development. While continued model refinement, validation, and ethical oversight remain crucial, AI-intgerated pharmaceutical research indicates growing maturity and transformative potential.

Empowering Healthcare Through AI: The Development of Thalassemia NusaCare for Early Detection of Genetic Blood Disorders in Indonesia Samuel, Thea; Jyoti, Chaitanya; Samuel, Lydia
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.944

Introduction Thalassemia is a prevalent inherited hemoglobinopathies in Indonesia, with an estimated carrier rate of 3-10% of the population. Under-resourced areas struggle with limited diagnostic services like genetic testing or hemoglobin electrophoresis. Prevention and clinical management by early screening and detection of potential thalassemia carriers are critical. This opens the opportunity to leverage computer vision and on-device machine learning to develop an iOS-based application, providing a digital anamnesis tool that is affordable and accessible for early thalassemia risk assessment. Methods Large, diverse datasets were collected to compile the clinical reports and to conduct the AI training. The system architecture of Thalassemia NusaCare AI consists of three integrated computational modules: Vision-Based Analysis using MobileNetV3 for facial and blood image detection, CBC laboratory data Interpretation using OCR and decision-tree algorithms. Digital Anamnesis uses adaptive, federated learning for accurate, real time Thalassemia risk prediction. Results Preliminary testing using a curated dataset (n=200 images, 120 lab entries, 80 questionnaire records) leads to a mean classification accuracy of 91.3% for detecting thalassemia major, minor, and non-thalassemic anemia, demonstrating high operational efficiency. Hybrid ensemble models result in an F1-score of 0.88 and enhanced sensitivity by 12% relative to single-input models. User experience testing with early adopters also suggested strong usability and intuitiveness (SUS = 89.2). Conclusion Thalassemia NusaCare AI integrates edge AI and inclusive design to deliver adaptive diagnostics in low-connectivity areas. Combining visual, numerical, and behavioral data, enabling on-device screening that aligns with Indonesia’s “Thalassemia-Free 2045” through federated learning and clinical collaboration.

Pharmacogenomic Regulation Of The NF-KB-NRF2 Axis By Curcumin: A Precision Molecular Approach to Inflammation and Oxidative Stress Alisya, Questa Soundri Alisya; Khairunnisa, Nadiah
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.948

Introduction: Chronic inflammation and oxidative stress are major mechanisms in degenerative diseases, including cancer, diabetes, and cardiovascular disorders. The NF-kB and Nrf2 pathways play a role in maintaining redox balance and inflammatory response. Curcumin, the main bioactive compound of Curcuma longa L., can simultaneously modulate both pathways through pharmacogenomic mechanisms influenced by individual genetic variations. Methods: This study used the Systematic Literature Review method in accordance with the PRISMA 2020 guidelines. Searches were conducted in PubMed, Scopus, ScienceDirect, and Google Scholar until October 2025 using the keywords “Curcumin,” “NF-kB,” “Nrf2,” “Oxidative Stress,” and “Pharmacogenomics.” Studies assessing the molecular modulation of NF-kB/Nrf2 by curcumin and gene-dependent effects were included. Results and Discussion: A total of 31 studies met the inclusion criteria, including in vitro, in vivo, in silico, and clinical studies. Curcumin suppressed NF-kB activation and activated Nrf2/HO-1, thereby reducing ROS and proinflammatory cytokines. Variations in the ERCC5 rs751402 gene, as well as the expression of SLC7A11 and ATAD3A/B, influenced the cellular response to curcumin. In silico and network pharmacology analyses revealed multigenic targets related to inflammation and oxidative stress. Nanoformulations enhance bioavailability and clinical immune response. Conclusion: Curcumin acts as a dual-regulator pharmacogenomic agent that balances the NF-kB and Nrf2 pathways, reducing inflammation and oxidative stress in a gene-dependent manner. These findings support its potential as a natural biomolecule for the development of precision therapies for chronic diseases involving inflammation and oxidative stress. Keywords: Curcumin, NF-kB, Nrf2, Oxidative Stress, Pharmacogenomics

Cardiovascular Adverse Event Risk in Rheumatoid Arthritis Patients Treated with JAK Inhibitor Tofacitinib versus TNF Inhibitors: a Systematic Review, Meta Analysis, and Meta Regression Kynaya, Erlangga Masykur; Salfistra, Nadia Ramadhina; Hanun, Jauza' 'Athifah
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.949

Rheumatoid arthritis (RA) is a chronic autoimmune disease, often requiring potent therapies like Tofacitinib or TNF inhibitors. Yet the comparative cardiovascular safety profile of these agents remains a critical and evolving concern. Previous meta-analysis revealed major adverse cardiovascular events (MACE) and thromboembolism was prevalent in tofacitinib treated patients. However, the impact of patient comorbidities on cardiovascular adverse events remains uncertain, requiring systematic assessment through meta-analysis and meta-regression. This study aims to assess the risk of cardiovascular adverse events in RA patients treated with tofacitinib versus TNF inhibitors and to evaluate the influence of baseline comorbidities through meta-regression. A comprehensive search of PubMed, Scopus, Scilit, and Epistemonikos identified RCTs and observational studies up to 2025. Random-effects meta-analysis in R estimated pooled OR and HR for MACE and thromboembolism, while patient comorbidities were evaluated through meta-regression. Four studies (n = 62,009) met inclusion criteria. Tofacitinib was associated with increased risk of MACE (HR = 1.33; 95% CI 1.08–1.65; p = 0.008; I² = 0%) and thromboembolism (HR = 1.79; 95% CI 1.23–2.60; p = 0.002; I² = 37.8%) compared with TNF inhibitors. Meta-regression revealed no significant effect of age, sex, hypertension, diabetes, smoking, heart failure, coronary artery disease, venous thromboembolism history, or corticosteroid use on these risks. Tofacitinib increases the risk of MACE and thromboembolism in RA patients compared with TNF inhibitors, independent of common cardiovascular comorbidities and baseline characteristics.

Exploring the Role of Mitochondria in Alzheimer with Network Pharmacology: A Bioinformatics Analysis Riena, Nadya Ratna; Novalina, Fellen; Heng, Kahtleen Riani
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.950

Alzheimer’s disease (AD) is a progressive neurodegenerative disease marked by the pathological accumulation of beta-amyloid peptide and hyperphosphorylated tau. Growing body of evidence indicates that mitochondrial dysfunction plays a pivotal role in AD pathogenesis, by inducing neurotoxicity through the formation of oxidative stress and reactive oxygen species (ROS). This study aims to investigate relevant mitochondrial proteins in Alzheimer by employing network pharmacology. Protein-coding genes associated with AD were identified from the GeneCards database, extracting only genes scoring >1 in relevancy. Datasets associated with mitochondria were extracted from the STRING database. 621 overlapping proteins from both keywords were further enriched and topologically analyzed. This study employed enrichment analyses using ShinyGO to identify relevant biological, cellular, and molecular processes, in addition to disease pathways. Topology analyses were conducted through STRING and Cytoscape by implementing eight different centrality parameters and clustering, the genes were further curated to obtain pivotal proteins in AD and their dysregulation. Aligned with our enrichment analyses, the proteins topologically relevant were components of the mitochondrial oxidative phosphorylation (OXPHOS) pathway, crucial to the respiratory electron transport chain and ATP synthesis system. This study provides a foundation for the discovery of multi-target drugs in AD therapy.

Comparative Efficacy and Safety of Limus-Eluting Stents in Acute Coronary Syndrome in Asian People: A Network Meta-Analysis and Bioinformatics Study Prazeva, Marista; Hendrawan, Adha; Habiby, Farhan
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.951

Introduction: Evidence on the relative performance of limus-eluting stents (LES) in acute coronary syndrome (ACS) among Asian patients is mixed, and formal rankings with biological context are limited. We compared LES and examined drug-specific mechanisms. Methods: Randomized trials of ACS patients undergoing PCI with 12-month outcomes were identified systematically. A frequentist network meta-analysis combined 19 trials (n=25,642) to estimate odds ratios (ORs) for major adverse cardiovascular events (MACE) and mortality and to derive treatment ranks (P-scores). Bioinformatics included molecular docking to FKBP12/mTOR/VEGFR2, ADMET/toxicity prediction, protein–protein interaction networks, and KEGG/GO enrichment. Results and Discussion: All limus stents lowered 12-month MACE versus paclitaxel (ZES 0.46 [0.34–0.64]; EES 0.55 [0.41–0.71]; SES 0.58 [0.46–0.72]; BES 0.60 [0.42–0.86]). Differences within the limus class were small (ZES vs SES 0.80 [0.62–1.06]). Rankings favored zotarolimus (SUCRA 0.94), followed by everolimus (0.64) and sirolimus (0.50); biolimus (0.42) ranked below, and paclitaxel was lowest. Mortality did not differ. Docking indicated stronger binding of limus agents to FKBP12/mTORC1 than paclitaxel, and toxicity models suggested a wider safety margin for limus agents (everolimus LD50 2,500 mg/kg; paclitaxel 134 mg/kg). Enrichment analyses highlighted PI3K–Akt/mTOR pathways relevant to vascular healing. Conclusion: In Asian ACS, LES outperform paclitaxel at 12 months. Zotarolimus ranks first, with everolimus and sirolimus performing comparably. The clinical ranking aligns with predicted target engagement and toxicity profiles.

Potential of Bioactive Peptides From Blanak Fish (Moolgarda Seheli) as Multitarget Therapy for Non-small Cell Lung Cancer: A Cancer-informatics Study Ramadhana, Reza; Maulana, Rafi; Al Habsy, Muhammab Nandito
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.952

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer with a high mortality rate and resistance to conventional therapy. Moolgarda seheli is known to produce bioactive compounds, but its potential against NSCLC still needs to be explored. This study aims to evaluate the pharmacokinetic profile, pharmacodynamics, and potential of M. seheli peptides as a multitarget agent for NSCLC through an in silico approach. Twelve M.seheli peptides were modeled using UCSF Chimera. Pharmacokinetic and pharmacodynamic predictions were performed using SwissADME, ProTox-3.0, and AllerTop. Membrane permeability was evaluated using PerMM. Target protein structures were obtained from PDBJ. Molecular docking was performed with MOE, then validated through molecular dynamics simulation (MD) using YASARA. Plasmid construction was performed in silico using ApE v2.0.36. Pharmacokinetic and pharmacodynamic profiles indicate the AVMAPIVA peptide has favorable distribution, metabolism, and excretion, as well as non-toxic and non-allergenic properties. The AVMAPIVA peptide exhibits strong affinity for CDK4 (-10.75 kcal/mol), BRAF (-11.60 kcal/mol), AKT1 (-10.79 kcal/mol), VEGFR2 (-10.73 kcal/mol), and EGFR (-10.47 kcal/mol). PerMM results indicate good membrane penetration ability. MD simulations confirm the stability of the complex. The results of the study indicate that the AVMAPIVA peptide is non-toxic, non-allergenic, stable in biological environments, and capable of penetrating cell membranes and inhibiting proliferation, migration, and angiogenesis in NSCLC. peptide from M. seheli has potential as a multitarget therapy for NSCLC with a good druglikeness profile. In vitro and in vivo experimental studies are needed for further validation of efficacy and safety. Keywords: Moolgarda seheli, Multitarget, NSCLC, Peptide-based therapy, Bioinformatics.

Associations Between Genetic Variants and Adverse Effects of Gefitinib in Non-small Cell Lung Cancer: A Systematic Review Rangga Pradipa, Agya Marsaa; Al Ayyubi, Muhammad Shalahudin; Romadhona, Sabila
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.953

Introduction: Lung cancer remains the leading cause of cancer-related death worldwide, with non–small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Gefitinib is a tyrosine kinase inhibitor frequently used in NSCLC with favorable outcome. However, many patients develop severe adverse effects which might be influenced by genetic variability. Therefore, we aim to systematically review the gene variants and its association with adverse effects of gefitinib in NSCLC patients. Methods: A systematic search was conducted according to PRISMA guidelines across PubMed, Scopus, and Cochrane. Studies investigating the association between genetic variations with adverse effects following gefitinib in NSCLC were included. Extracted data encompassed study and patient characteristics, adverse effects, and identified gene variations. Risk of bias was assessed using the RoB-2 for randomized trials and Newcastle–Ottawa Quality Assessment Scale for cohort and case–control studies. Results: Nineteen studies involving 2.087 patients were included, with Japanese populations being the most studied. Polymorphisms in EGFR and ABCG2 were among the most studied genes. Rash, diarrhea, and hepatotoxicity are the most common adverse effects reported. Poor metabolizers of CYP2D6 and CYP3A53/3, and variations in ABCG2, ABCB1, and EGFR were associated with higher incidence of adverse effects. However, several studies demonstrated no associations between gene variations with adverse effects. Conclusion: Genetic variations in ABCG2, ABCB1, CYP2D6, CYP3A53/3, and EGFR may influence gefitinib-associated adverse effects, highlighting the need of pharmacogenomic testing to guide personalized treatment and improved patient safety. Keywords: Pharmacogenomics, Genetic Variants, Gefitinib, Non-Small Cell Lung Cancer, Adverse Effects

Novel of Tuberculosis Vaccine Candidates through In Silico and In Vivo Analysis of Single Epitope Protein PE-PGRS Mycobacterium Tuberculosis Adha, Muhammad Alghifary; Maulana, Rafi; Mifindra, Rafhy
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.955

Tuberculosis (TB) is an infectious disease that remains a serious global health threat. The use of the Bacille Calmette–Guérin (BCG) TB vaccine has so far shown unsatisfactory results due to its inconsistent and limited effectiveness. In this study, a comprehensive preclinical study pipeline was developed to design a novel single-epitope subunit vaccine targeting the PE_PGRS protein family of Mycobacterium tuberculosis. VaxiJen screened antigenic proteins, IEDB and NetMHCpan predicted B- and T-cell epitopes. Selected epitopes were assembled with linkers and an adjuvant. The construct was expressed, purified, and tested in vivo in mice for antibody and cytokine responses. The construct result showed, which had a molecular weight of 35.1 kDa and an instability score of 16.58, was found to be stable, soluble, and somewhat hydrophilic by physicochemical examination. The three-dimensional model showed a tight and stable fold that was dominated by ?-sheets and ?-helices. Strong binding affinities with MHC class I (?G = ?22.7 kcal/mol) and class II (?G = ?10.9 kcal/mol) were confirmed by molecular docking and PRODIGY studies. In the in vivo test, the single epitope exposure group had an average value of 0.090 ± 0.017. This indicates that single epitope exposure provides a significant effective antigen presentation and T-cell activation and increase in the measured parameters compared to the control group. Collectively, these findings highlight the potential of the designed single-epitope construct as a safe, stable, and immunogenic vaccine candidate against M. tuberculosis, meriting further experimental validation.

Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs Putera, Rizky; Onggowasito, Livilia Abigail; Kynaya, Erlangga Masykur
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Book of Abstrack RCIMS 2025
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.vi.961

Psoriasis is a chronic immune-mediated disease affecting 1–3% of the population worldwide and often impairs quality of life, with moderate-to-severe cases requiring systemic therapy. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor that modulates IL-23, IL-12, and type I interferon pathways, has emerged as a promising oral therapy. However, trial findings remain inconsistent, highlighting the need for systematic evaluation of its efficacy and safety versus placebo. A comprehensive literature search of PubMed, Scopus, Scilit, and ScienceDirect was performed to identify randomized controlled trials published up to 2025 comparing deucravacitinib with placebo in psoriasis. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and meta-analysis was conducted with Rstudio with random effect model and REML estimator. Seven RCTs (n = 3,014) were included. Deucravacitinib significantly improved PASI-75 (OR = 9.85; 95% CI 5.11–19.01; p < 0.0001), PASI-90 (OR = 14.29; 95% CI 9.14–22.35; p < 0.0001), and PASI-100 (OR = 12.03; 95% CI 5.55–26.09; p < 0.0001), as well as sPGA 0/1 (OR = 14.28; 95% CI 9.30–23.62; p < 0.0001). Quality-of-life outcomes also improved: PSSD-0 (OR = 7.60; 95% CI 2.73–21.16; p = 0.0001) and DLQI 0/1 (OR = 6.27; 95% CI 4.68–8.41; p < 0.0001). Upper respiratory tract infection and acne were more frequent with deucravacitinib, while other adverse events were comparable to placebo. Meta-regression showed dose dependence for DLQI 0/1 (p = 0.02) and PSSD-0 (p = 0.01), but not for adverse events. Deucravacitinib demonstrates significant efficacy and acceptable safety in psoriasis treatment. Long-term studies are warranted to confirm its sustained safety profile. Keywords: Deucravacitinib, Psoriasis, TYK2 Inhibitor, Efficacy

Page 1 of 2 | Total Record : 20

1 2

Filter by Year

2025 2025

Filter By Issues

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Norbertus Marcell Prayogi

Contact Email
editor.jimki.bapin@gmail.com

Phone
+6281372545321

Journal Mail Official
editor@jimki.bapin.or.id

Editorial Address
Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Norbertus Marcell Prayogi

Contact Email editor.jimki.bapin@gmail.com

Phone +6281372545321

Journal Mail Official editor@jimki.bapin.or.id

Editorial Address Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location Kota adm. jakarta pusat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Norbertus Marcell Prayogi

Contact Email
editor.jimki.bapin@gmail.com

Phone
+6281372545321

Journal Mail Official
editor@jimki.bapin.or.id

Editorial Address
Jl. Dr. G.S.S.Y. Ratulangi No. 29, Menteng, Jakarta Pusat 10350

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA